Newsletters


Filter by volume

Agenus on Twitter

$AGEN listed as one of biggest #ASCO21 risers in @evaluatevantage stock round-up. Agenus presented on differentiated activity of anti-PD-1 antibody balstilimab & new clinical data on AGEN2373, a CD137 agonist antibody evaluate.com/vantage/articl…

Agenus at #ASCO21 Agenus’ CMO @ODayMD offers his thoughts on Agenus' #AI VISION platform and AGEN2373 data presented @ASCO. Click to read more: investor.agenusbio.com/news-releases/…

test Twitter Media - Agenus at #ASCO21
Agenus’ CMO @ODayMD offers his thoughts on Agenus' #AI VISION platform and AGEN2373 data presented @ASCO. Click to read more: https://t.co/6DQC2Q75te https://t.co/CSqifhWc0R

Agenus’ Presentations at #ASCO21 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373 Bal demonstrates superior tumor killing potential in a VISION study. AGEN2373 shows no liver toxicity; combo trials are planned investor.agenusbio.com/news-releases/…

Agenus' collaboration with @bmsnews will allow us to accelerate the advancement of our differentiated pipeline while also giving us greater optionality as we pursue the best development strategy for each individual asset. investor.agenusbio.com/news-releases/…

test Twitter Media - Agenus' collaboration with @bmsnews will allow us to accelerate the advancement of our differentiated pipeline while also giving us greater optionality as we pursue the best development strategy for each individual asset.

https://t.co/hrT0IaZQ95 https://t.co/aTXoTlwhUj

Agenus newsletter now available: Setting the Stage for Innovation with Our Own PD-1 Having a PD-1 is critical to our I-O strategy. It provides commercial flexibility & opportunities to advance this agent for strategic combinations Click to read: agenusbio.com/agenusnews-vol…

Agenus to Participate in Fireside Chat at the @Jefferies 2021 Virtual Healthcare Conference Agenus' President and COO @jbuell01 will participate in a fireside chat on Friday, June 4, 2021 from 10:30am - 10:55am ET investor.agenusbio.com/news-releases/…

May is #NationalCancerResearchMonth, and we’re highlighting the incredible work our scientists do advancing #immunotherapy #NCRM21 #researchsaveslives

test Twitter Media - May is #NationalCancerResearchMonth, and we’re highlighting the incredible work our scientists do advancing #immunotherapy

#NCRM21 #researchsaveslives https://t.co/SmrSvIFLh3

Listen to the latest @BioCentury podcast episode to hear about Agenus’ collaboration with @bmsnews and AGEN1777’s bispecific and Fc-enhanced design #TIGIT #oncology #Immunotherapy biocentury.com/article/636637…

REMINDER 🧬 @BiotechCH “Biotech Clubhouse: Sunday Hangout” - reviewing news of the week w/ me, @bradloncar, & @daphnezohar Join us tomorrow Sun May 23 at 4:00pm EDT w/ special guest @Agenus_Bio President/COO @jbuell01 to discuss their @bmsnews TIGIT deal! joinclubhouse.com/event/PAAjr28O Retweeted by Agenus Inc. ($AGEN)

Like the rest of Agenus' differentiated pipeline, AGEN1777 is optimally designed to address an unmet need. rb.gy/dpntx4

We are proud to collaborate with industry leader @bmsnews to develop this Fc enhanced anti-TIGIT bispecific while continuing to advance our other innovations like our Fc enhanced anti-CTLA-4 AGEN1181 to serve patients with cancer and disrupt the IO space #immunotherapy #TIGIT

@bmsnews makes potential $1.56 billion commitment to Agenus' antibody program #biotechnology #antibodies #pharmaceutical hubs.li/H0NzV7q0 Retweeted by Agenus Inc. ($AGEN)

Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target biopharmadive.com/news/bristol-m… by @NedPagliarulo $BMY $AGEN Retweeted by Agenus Inc. ($AGEN)

A Lexington biotech firm has signed its largest licensing deal ever for a tumor-fighting antibody that is still in preclinical development.​ bizjournals.com/boston/news/20… Retweeted by Agenus Inc. ($AGEN)

BMS to pay up to $1.56bn for Agenus’ bispecific antibody programme feedproxy.google.com/~r/Pharmatimes… #pharmanews #lifesciences Retweeted by Agenus Inc. ($AGEN)

Bristol Myers Squibb buys rights to Agenus's anti-TIGIT candidate in $1.56 billion deal @bmsnews @Agenus_Bio #Immunotherapy bit.ly/3bH0TsO Retweeted by Agenus Inc. ($AGEN)

Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts Balstilimab shows a differentiated profile both clinically and preclinically. AGEN2373 has been well tolerated in a dose escalation trial with no liver toxicity observed investor.agenusbio.com/news-releases/…

.@bmsnews is paying $200M for global rights to an @Agenus_Bio bispecific antibody that preclinical research shows has potential to best rest of the class. If it reaches the market, $AGEN could earn up to $1.36B in milestones, via @frankvinluan medcitynews.com/2021/05/bristo… $BMY #cancer Retweeted by Agenus Inc. ($AGEN)

TIGIT fidgets lessen as Agenus’ mystery preclinical bispecific bags BMS pact worth up to $1.3B-plus… bioworld.com/articles/50720… Retweeted by Agenus Inc. ($AGEN)

Bristol Pays Out $200m For Agenus' Preclinical Bispecific TIGIT bit.ly/3bAGXb8 #PharmaScrip Retweeted by Agenus Inc. ($AGEN)